Stryker Corporation (NYSE:SYK) VP M Kathryn Fink sold 150 shares of the company’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $154.46, for a total value of $23,169.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Stryker Corporation (SYK) traded down $3.51 during mid-day trading on Monday, hitting $152.36. The company had a trading volume of 1,351,039 shares, compared to its average volume of 1,182,374. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.37 and a quick ratio of 1.61. The stock has a market cap of $57,020.00, a P/E ratio of 24.70, a PEG ratio of 2.45 and a beta of 0.78. Stryker Corporation has a 52-week low of $111.22 and a 52-week high of $160.62.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 26th. The medical technology company reported $1.52 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.02. The firm had revenue of $3.01 billion for the quarter, compared to the consensus estimate of $2.97 billion. Stryker had a return on equity of 24.11% and a net margin of 14.67%. The company’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.39 EPS. sell-side analysts expect that Stryker Corporation will post 6.47 EPS for the current fiscal year.

SYK has been the topic of several recent analyst reports. Royal Bank Of Canada reaffirmed a “buy” rating and issued a $155.00 price target on shares of Stryker in a research note on Friday, September 1st. Argus reaffirmed a “buy” rating and issued a $160.00 price target on shares of Stryker in a research note on Tuesday, August 29th. Zacks Investment Research lowered Stryker from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. Robert W. Baird raised Stryker from a “neutral” rating to an “outperform” rating and upped their price target for the company from $161.00 to $173.00 in a research note on Thursday, November 16th. Finally, Stifel Nicolaus upped their price target on Stryker from $158.00 to $168.00 and gave the company a “buy” rating in a research note on Friday, October 27th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and thirteen have given a buy rating to the stock. Stryker currently has an average rating of “Hold” and an average price target of $152.10.

Hedge funds have recently bought and sold shares of the stock. Acrospire Investment Management LLC purchased a new stake in Stryker during the 2nd quarter worth about $111,000. Motco boosted its position in shares of Stryker by 50.7% during the 2nd quarter. Motco now owns 826 shares of the medical technology company’s stock worth $115,000 after acquiring an additional 278 shares in the last quarter. San Francisco Sentry Investment Group CA boosted its position in shares of Stryker by 47.8% during the 3rd quarter. San Francisco Sentry Investment Group CA now owns 1,005 shares of the medical technology company’s stock worth $143,000 after acquiring an additional 325 shares in the last quarter. Bruderman Asset Management LLC acquired a new position in shares of Stryker during the 2nd quarter worth about $150,000. Finally, James Investment Research Inc. acquired a new position in shares of Stryker during the 2nd quarter worth about $155,000. Hedge funds and other institutional investors own 74.97% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://theolympiareport.com/2017/12/04/stryker-corporation-syk-vp-sells-23169-00-in-stock.html.

Stryker Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Insider Buying and Selling by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.